Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Statistics
  • Help & Advice
University of Warwick

The Library

  • Login

Effect of immunomodulatory medication on regional gray matter loss in relapsing–remitting multiple sclerosis — a longitudinal MRI study

Tools
- Tools
+ Tools

Bendfeldt, Kerstin, Egger, Hanspeter, Nichols, Thomas E., Loetscher, Patrick, Denier, Niklaus, Kuster, Pascal, Traud, Stefan, Mueller-Lenke, Nicole, Naegelin, Yvonne, Gass, Achim, Kappos, Ludwig, Radue, Ernst-Wilhelm and Borgwardt, Stefan. (2010) Effect of immunomodulatory medication on regional gray matter loss in relapsing–remitting multiple sclerosis — a longitudinal MRI study. Brain Research, Vol.1325 . pp. 174-182. ISSN 0006-8993

Full text not available from this repository.
Official URL: http://dx.doi.org/10.1016/j.brainres.2010.02.035

Abstract

Prevention of global gray matter (GM) volume changes in multiple sclerosis (MS) are an objective in clinical trials, but the effect of immunomodulatory medication on regional GM atrophy progression is unclear. MRIs from 86 patients with relapsing-remitting MS (RRMS) followed up for 24 months were analyzed using voxel-based morphometry. An analysis of covariance model (cluster threshold, corrected p<0.05) was used to compare GM volumes between baseline and follow-up while stratified by immunomodulatory medication (IM): Interferone INF-beta-1a (n=34), INF-beta-1b (n=16), glatiramer acetate (GA) (n=15), and no-immunomodulatory treatment (n=21). In the INF-beta-1a/1b group (n=50), significant GM volume reductions were observed during follow-up in fronto-temporal, cingulate and cerebellar cortical brain regions, without significant differences between the INF-beta-1a and INF-beta-1b patients. In the GA group and in unmedicated patients, no significant regional GM volume reductions were observed. In contrast to GA, INF-beta-1a/1b treatment was associated with GM volume reductions in hippocampal/parahippocampal and anterior cingulate cortex. This is the first longitudinal study investigating the effects of IMs on GM in RRMS. Results suggest differences in the dynamics of regional GM volume atrophy in differentially treated or untreated RRMS patients.

Item Type: Journal Article
Subjects: Q Science > QR Microbiology > QR180 Immunology
R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Divisions: Faculty of Science > Statistics
Faculty of Science > WMG (Formerly the Warwick Manufacturing Group)
Library of Congress Subject Headings (LCSH): Multiple sclerosis -- Immunological aspects, Immune response -- Regulation, Multiple sclerosis -- Magnetic resonance imaging, Longitudinal method
Journal or Publication Title: Brain Research
Publisher: Elsevier Science BV
ISSN: 0006-8993
Date: 14 April 2010
Volume: Vol.1325
Number of Pages: 9
Page Range: pp. 174-182
Identification Number: 10.1016/j.brainres.2010.02.035
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
URI: http://wrap.warwick.ac.uk/id/eprint/38173

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item View Item
twitter

Email us: publications@warwick.ac.uk
Contact Details
About Us